JNCCN 360

Editor:

Robert I. Haddad, MD

Advertisement

Advertisement

Robert I. Haddad, MD, on Thyroid Cancer NCCN Clinical Practice Guidelines in Oncology®: Expert Perspective

Enrique Grande, MD, PhD, on Targeted Treatment for Thyroid Cancer

Lori J. Wirth, MD, on RET-Altered Thyroid Cancer: Results From a Study on Selpercatinib

Recent

Relationship Between Thyroid Dysfunction and Risk of Breast and Thyroid Cancers

Understanding Resistance to Vandetanib in Medullary Thyroid Carcinoma

ASCO20: Update on RAS-Mutated Sporadic Medullary Thyroid Cancer

COVID-19 and Head/Neck Cancer: International Consensus on Surgical Practice

Published

Medical Literature

Selpercatinib Treatment of RET-Mutant Medullary Thyroid Cancers

Mexican Study Focuses on Clinical Management of Pediatric Thyroid Cancer

Diagnosis of High-Suspicion Thyroid Nodules Using Elastography

Are Thyroglobulin Antibody Levels a Reliable Indicator of Thyroid Cancer Recurrence?

Ongoing

Differentiated thyroid cancer (DTC): therapeutic updates and optimizing treatment

A Unique Approach to Assessing the Risk of Indeterminate Thyroid Nodules

Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma

Is Radioiodine Tx Overused in Low-Risk Thyroid Cancer?

Available

Clinical Trials

Memorial Sloan Kettering Memorial Center

University of Michigan Cancer Center

Sarah Cannon Research Institute at HealthONE

Advertisement

Advertisement

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.